IDEXX Laboratories (IDXX) stock
NASDAQ
As of the Nov 5, 2026 close (U.S. Eastern)
Events and reference metrics · 1
- Market cap
- $52.8B
- As of Nov 5, 2026
- P/E
- 44.78x
- Trailing twelve months
- P/B
- 28.27x
- Latest reported equity
- P/S
- 11.33x
- Trailing twelve months
- ROE
- 63.1%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 5, 2026 and may differ from the current price.
- Market cap
- $52.8B
- As of Nov 5, 2026
- P/E
- 44.78x
- Trailing twelve months
- P/B
- 28.27x
- Latest reported equity
- P/S
- 11.33x
- Trailing twelve months
- ROE
- 63.1%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 5, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 5, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
44.78x
P/B
28.27x
P/S
11.33x
Earnings and dividend metrics▾
Earnings
EPS
$14.94
Earnings per share
BPS
$23.66
Book value per share
ROE
63.1%
Return on equity
- EPS — what one share earned over the last four quarters. This company earned $14.94 per share.
- BPS — net assets divided by the number of shares. Each share is backed by $23.66 of net assets.
- ROE — how much the company earned on shareholder equity over a year: 63.1%.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsJul–Sep 2026(FY2026 Q3)
Revenue increased 9.9% from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
Revenue · same quarter, three years
Year-ago quarter $1.11B+9.9%
$976M
Jul–Sep '24
$1.11B
Jul–Sep '25
$1.21B
Jul–Sep '26
The next earnings date has not been confirmed yet.
ⓘ Notes on these figures▾
- Results for Jul–Sep 2026 are from the 10-Q submitted to SEC EDGAR on Nov 2, 2026.
- Earnings per share increased 17.9% from the same quarter a year earlier.
- Revenue increased 9.9% from the same quarter a year earlier.
- Operating income increased 13.2% from the same quarter a year earlier.
- Net income increased 15.3% from the same quarter a year earlier.
Filed Nov 2, 2026 · 10-Q · SEC EDGAR · View original
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- Underberg Sharon E.EVP, GC & Corporate Secretary · Nov 4, 2026Open-market sale8,906 shares · $6.1MAvg. price $688.5925
Show 3 price lots
- 6,348 shares × $688.2475$4.4M
- 1,503 shares × $689.0462$1.0M
- 1,055 shares × $690.0222$728K
- MAZELSKY JONATHAN JAYExecutive Chair of the Board · Nov 4, 2026Open-market sale25,140 shares · $17.7MAvg. price $703.1899
Show 13 price lots
- 4,540 shares × $701.3564$3.2M
- 4,075 shares × $699.3278$2.8M
- 3,950 shares × $703.449$2.8M
- 2,136 shares × $702.2107$1.5M
- 1,945 shares × $698.2625$1.4M
- 1,840 shares × $707.8445$1.3M
- 1,667 shares × $700.325$1.2M
- 1,501 shares × $710.1207$1.1M
- 1,300 shares × $709.0019$922K
- 840 shares × $707$594K
- 775 shares × $711.3085$551K
- 331 shares × $711.9475$236K
- 240 shares × $705.59$169K
- Lane MichaelExecutive Vice President · Nov 4, 2026Open-market sale3,979 shares · $2.7MAvg. price $688.6424
Show 3 price lots
- 2,059 shares × $689.7$1.4M
- 1,677 shares × $687.4586$1.2M
- 243 shares × $687.85$167K
- JUNIUS DANIEL MDirector · Nov 4, 2026Open-market sale1,200 shares · $845KAvg. price $704.0738
Show 2 price lots
- 700 shares × $705.78$494K
- 500 shares × $701.685$351K
- MAZELSKY JONATHAN JAYExecutive Chair of the Board · Nov 4, 2026Option exercise25,140 shares · $4.5MAvg. price $178.26108,943 shares held after
- Underberg Sharon E.EVP, GC & Corporate Secretary · Nov 4, 2026Option exercise8,906 shares · $2.6MAvg. price $288.7816,075 shares held after
- HOOLEY JOSEPH LDirector · Oct 30, 2026Grant or award48 shares · $26KAvg. price $551.21373 shares held after
- Kingsley Lawrence DDirector · Sep 4, 2026Open-market sale2,203 shares · $1.2MAvg. price $532.08269,568 shares held after
- Kingsley Lawrence DDirector · Sep 4, 2026Option exercise2,203 shares · $252KAvg. price $114.1711,771 shares held after
- Emerson AndrewEVP, CFO and Treasurer · Aug 20, 2026Option exercise265 shares · $47KAvg. price $178.264,507 shares held after
- Emerson AndrewEVP, CFO and Treasurer · Aug 20, 2026Shares withheld for taxes86 shares · $0Avg. price $04,421 shares held after
- HOOLEY JOSEPH LDirector · Jul 30, 2026Grant or award49 shares · $27KAvg. price $558.8325 shares held after
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsRecent filing summaries
Newest first by publication date · may differ from the filing date
- AI summary10-QIDEXX said gross profit margin rose 110 basis points for the quarter ended September 30, 2026. The company cited higher IDEXX VetLab consumable volumes, operational productivity improvements, and net price realization, which offset inflationary costs.Published Nov 3, 2026 · Filed Nov 2, 2026Read the summary →
- AI summary8-KIDEXX said revenue for Q3 2026 was $1,214 million, up 10% on both a reported and organic basis, and diluted earnings per share (EPS) were $4.01, up 18% as reported and 22% on a comparable basis.Published Nov 2, 2026 · Filed Nov 2, 2026Read the summary →
- AI summary8-KIDEXX Laboratories said shareholders approved amendments to the Corporation's Amended and Restated Certificate of Incorporation at the annual meeting held on May 12, 2026 to declassify the Board over 3 years and provide for the annual election of all directors beginning at the 2029 annual meeting of shareholders.Published Oct 1, 2026 · Filed May 15, 2026Read the summary →
- IDEXX said revenue for Q3 2026 was $1,214 million, up 10% on both a reported and organic basis, and diluted earnings per share (EPS) were $4.01, up 18% as reported and 22% on a comparable basis.Read the full analysis →
- IDEXX said gross profit margin rose 110 basis points for the quarter ended September 30, 2026. The company cited higher IDEXX VetLab consumable volumes, operational productivity improvements, and net price realization, which offset inflationary costs.Read the full analysis →
Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
IDEXX Laboratories (IDXX) stock information
NASDAQ
IDEXX Laboratories (IDXX) is listed on NASDAQ. Its market capitalization is about $52.8B. On trailing-twelve-month earnings the P/E ratio is 44.78, and the P/B ratio is 28.27. Return on equity is 63.1%. These figures are computed in-house from official filings and are reference information only.
IDEXX Laboratories — frequently asked questions
- What is the P/E ratio of IDEXX Laboratories (IDXX)?
- On a trailing-twelve-month basis, IDXX trades at a P/E ratio of 44.78. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of IDEXX Laboratories?
- IDXX has a market capitalization of about $52.8B. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.